Yang Meng
Regent Court, 30 Regent Street
Sheffield, ENG, United Kingdom
Sheffield, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
HHGSynergy: An Adaptive Heterogeneous Hypergraph Representation Learning Method for Anticancer Drug Synergy Prediction.
Journal: IEEE transactions on computational biology and bioinformatics
Published: December 25, 2025
Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
Journal: Journal of medical economics
Published: October 03, 2025
Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome.
Journal: Clinical and experimental medicine
Published: June 10, 2025
Impact of Mobilization Facilitated by Wearable Device Enhanced Patient Monitoring/Electrophysiology Pod-Based Feedback on Postoperative Complications Following Colorectal Cancer Surgery: Randomized Controlled Trial.
Journal: JMIR mHealth and uHealth
Published: December 25, 2024
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Journal: Targeted oncology
Published: March 28, 2023
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Journal: PharmacoEconomics
Published: September 13, 2022
Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy.
Journal: MedComm
Published: May 30, 2022
A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States.
Journal: Advances in therapy
Published: November 13, 2020
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
Journal: Journal of medical economics
Published: May 16, 2020
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Journal: Clinical genitourinary cancer
Published: April 29, 2020
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Journal: Journal of medical economics
Published: November 14, 2018
Last Updated: 09/26/2026